Olmesartán Mylan (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmesartán Mylan, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients and to reduce the risk of cardiovascular complications associated with hypertension.

GNH USA supplies Olmesartán Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil belongs to the angiotensin II receptor blocker class and is used to manage conditions related to elevated vascular tone. - Essential hypertension: reduces systolic and diastolic blood pressure, helping to prevent stroke and heart attack. - High blood pressure in adults: provides long‑term control of blood pressure when lifestyle measures are insufficient. - Hypertensive heart disease: lowers cardiac afterload, contributing to improved cardiac function.

Olmesartan medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after the first dose. - Headache: mild to moderate intensity, often transient. - Fatigue: feeling unusually tired without exertion. - Abdominal pain: mild discomfort in the stomach area. - Nasal congestion: stuffy nose or mild sinus pressure.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Hyperkalemia: elevated blood potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function, indicated by reduced urine output or rising creatinine. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Myocardial infarction: rare reports of heart attack, particularly in patients with existing coronary disease.

Before initiating therapy with Olmesartan medoxomil, several safety considerations should be reviewed. - Pregnancy: Category D – avoid use during pregnancy due to risk of fetal toxicity. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes in patients with liver disease. - Concomitant potassium‑sparing agents: avoid combined use to reduce risk of hyperkalemia. - Blood pressure monitoring: check regularly to ensure adequate control and avoid hypotension. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal dysfunction and hyperkalemia. - ACE inhibitors: concurrent use can raise the likelihood of angioedema and severe hypotension. - Potassium‑rich supplements or potassium‑sparing diuretics: may precipitate dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can diminish antihypertensive effect and affect renal function. - Diuretics (thiazide or loop): may enhance blood‑pressure lowering, requiring dose adjustment. - Lithium: ARBs may increase lithium levels, necessitating serum monitoring. - Other antihypertensives: additive blood‑pressure reduction may require careful titration. - CYP450 inhibitors (e.g., ketoconazole): may modestly increase olmesartan exposure, warranting observation.